PMID-37739806 – SLU-PP-332 Alleviates Metabolic Syndrome
Kim SH, Teng S, Guo W, Burris TP. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024;388(1):232-240.
Quick Reference
| Property | Value |
|---|---|
| PMID | 37739806 |
| DOI | 10.1124/jpet.123.001874 |
| Year | 2024 |
| Journal | Journal of Pharmacology and Experimental Therapeutics |
| Study Type | Animal in vivo |
| Evidence Level | V |
| Sample | Diet-induced obese mice |
| Peptide(s) Studied | SLU-PP-332 |
Key Findings
- SLU-PP-332 (pan-ERR agonist) reduced body weight gain in diet-induced obese (DIO) mice
- Decreased fat mass accumulation without affecting lean mass
- Improved glucose tolerance and insulin sensitivity
- Reduced hepatic steatosis (fatty liver)
- Increased energy expenditure and fatty acid oxidation markers
- Mimicked exercise-induced metabolic improvements without actual exercise
- Effects were ERRalpha-dependent as shown by genetic knockout experiments
Study Design
Preclinical study in diet-induced obese mice. Animals received SLU-PP-332 (approximately 50 mg/kg/day by IP injection) or vehicle for several weeks. Body composition, metabolic parameters, glucose tolerance tests, and tissue analyses performed.
Limitations
- Animal study only; no human data
- High dose relative to potential human equivalent (~280 mg/day for 70 kg human)
- IP injection route; oral bioavailability is poor
- Single research group (Burris lab at Washington University in St. Louis/University of Florida)
- Long-term safety of sustained ERR agonism unknown
Clinical Relevance
Establishes SLU-PP-332 as a proof-of-concept exercise mimetic that can ameliorate metabolic syndrome features in obese mice. The finding that fat loss occurs without lean mass reduction is clinically appealing. However, the enormous gap between effective mouse doses and commercially available capsule doses (500 mcg vs ~280 mg HED) raises significant questions about clinical efficacy at current supplement dosing.
Related
#research #animal-in-vivo #SLU-PP-332 #evidence-level-V